IBDEI06X ; ; 20-FEB-2013
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 20, 2013
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,9075,0)
 ;;=V15.89^^74^636^55
 ;;^UTILITY(U,$J,358.3,9075,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9075,1,4,0)
 ;;=4^V15.89
 ;;^UTILITY(U,$J,358.3,9075,1,5,0)
 ;;=5^Personal H/O Exposure To Persian Gulf Region
 ;;^UTILITY(U,$J,358.3,9075,2)
 ;;=^295291
 ;;^UTILITY(U,$J,358.3,9076,0)
 ;;=V11.3^^74^636^48
 ;;^UTILITY(U,$J,358.3,9076,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9076,1,4,0)
 ;;=4^V11.3
 ;;^UTILITY(U,$J,358.3,9076,1,5,0)
 ;;=5^Personal H/O Alcoholism
 ;;^UTILITY(U,$J,358.3,9076,2)
 ;;=^295252
 ;;^UTILITY(U,$J,358.3,9077,0)
 ;;=V15.07^^74^636^49
 ;;^UTILITY(U,$J,358.3,9077,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9077,1,4,0)
 ;;=4^V15.07
 ;;^UTILITY(U,$J,358.3,9077,1,5,0)
 ;;=5^Personal H/O Allerlgy To Latex
 ;;^UTILITY(U,$J,358.3,9077,2)
 ;;=^322043
 ;;^UTILITY(U,$J,358.3,9078,0)
 ;;=V13.4^^74^636^50
 ;;^UTILITY(U,$J,358.3,9078,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9078,1,4,0)
 ;;=4^V13.4
 ;;^UTILITY(U,$J,358.3,9078,1,5,0)
 ;;=5^Personal H/O Arthritis
 ;;^UTILITY(U,$J,358.3,9078,2)
 ;;=^295267
 ;;^UTILITY(U,$J,358.3,9079,0)
 ;;=V12.72^^74^636^51
 ;;^UTILITY(U,$J,358.3,9079,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9079,1,4,0)
 ;;=4^V12.72
 ;;^UTILITY(U,$J,358.3,9079,1,5,0)
 ;;=5^Personal H/O Colon Polyps
 ;;^UTILITY(U,$J,358.3,9079,2)
 ;;=^303401
 ;;^UTILITY(U,$J,358.3,9080,0)
 ;;=V12.59^^74^636^52
 ;;^UTILITY(U,$J,358.3,9080,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9080,1,4,0)
 ;;=4^V12.59
 ;;^UTILITY(U,$J,358.3,9080,1,5,0)
 ;;=5^Personal H/O Congestive Heart Failure
 ;;^UTILITY(U,$J,358.3,9080,2)
 ;;=^303399
 ;;^UTILITY(U,$J,358.3,9081,0)
 ;;=V45.81^^74^636^53
 ;;^UTILITY(U,$J,358.3,9081,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9081,1,4,0)
 ;;=4^V45.81
 ;;^UTILITY(U,$J,358.3,9081,1,5,0)
 ;;=5^Personal H/O Coronary Bypass
 ;;^UTILITY(U,$J,358.3,9081,2)
 ;;=^97129
 ;;^UTILITY(U,$J,358.3,9082,0)
 ;;=V15.84^^74^636^54
 ;;^UTILITY(U,$J,358.3,9082,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9082,1,4,0)
 ;;=4^V15.84
 ;;^UTILITY(U,$J,358.3,9082,1,5,0)
 ;;=5^Personal H/O Exposure To Asbestos
 ;;^UTILITY(U,$J,358.3,9082,2)
 ;;=^303406
 ;;^UTILITY(U,$J,358.3,9083,0)
 ;;=V15.85^^74^636^60
 ;;^UTILITY(U,$J,358.3,9083,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9083,1,4,0)
 ;;=4^V15.85
 ;;^UTILITY(U,$J,358.3,9083,1,5,0)
 ;;=5^Personal H/O Potentially Hazardous Body Fluids
 ;;^UTILITY(U,$J,358.3,9083,2)
 ;;=^303407
 ;;^UTILITY(U,$J,358.3,9084,0)
 ;;=V10.72^^74^636^56
 ;;^UTILITY(U,$J,358.3,9084,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9084,1,4,0)
 ;;=4^V10.72
 ;;^UTILITY(U,$J,358.3,9084,1,5,0)
 ;;=5^Personal H/O Hodgkin'S Disease
 ;;^UTILITY(U,$J,358.3,9084,2)
 ;;=^295237
 ;;^UTILITY(U,$J,358.3,9085,0)
 ;;=V15.3^^74^636^57
 ;;^UTILITY(U,$J,358.3,9085,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9085,1,4,0)
 ;;=4^V15.3
 ;;^UTILITY(U,$J,358.3,9085,1,5,0)
 ;;=5^Personal H/O Irradiation
 ;;^UTILITY(U,$J,358.3,9085,2)
 ;;=^295285
 ;;^UTILITY(U,$J,358.3,9086,0)
 ;;=V10.61^^74^636^32
 ;;^UTILITY(U,$J,358.3,9086,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9086,1,4,0)
 ;;=4^V10.61
 ;;^UTILITY(U,$J,358.3,9086,1,5,0)
 ;;=5^Hx Of Lymphoid Leukemia
 ;;^UTILITY(U,$J,358.3,9086,2)
 ;;=Hx of Lymphoid Leukemia^295232
 ;;^UTILITY(U,$J,358.3,9087,0)
 ;;=V12.03^^74^636^33
 ;;^UTILITY(U,$J,358.3,9087,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9087,1,4,0)
 ;;=4^V12.03
 ;;^UTILITY(U,$J,358.3,9087,1,5,0)
 ;;=5^Hx Of Malaria
 ;;^UTILITY(U,$J,358.3,9087,2)
 ;;=Hx of Malaria^303395
 ;;^UTILITY(U,$J,358.3,9088,0)
 ;;=V10.82^^74^636^34
 ;;^UTILITY(U,$J,358.3,9088,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9088,1,4,0)
 ;;=4^V10.82
 ;;^UTILITY(U,$J,358.3,9088,1,5,0)
 ;;=5^Hx Of Malignant Melanoma
 ;;^UTILITY(U,$J,358.3,9088,2)
 ;;=Hx of Malignant Melanoma^295240
 ;;^UTILITY(U,$J,358.3,9089,0)
 ;;=V10.62^^74^636^36
 ;;^UTILITY(U,$J,358.3,9089,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9089,1,4,0)
 ;;=4^V10.62
 ;;^UTILITY(U,$J,358.3,9089,1,5,0)
 ;;=5^Hx Of Myeloid Leukemia
 ;;^UTILITY(U,$J,358.3,9089,2)
 ;;=Hx of Myeloid Leukemia^295233
 ;;^UTILITY(U,$J,358.3,9090,0)
 ;;=V10.63^^74^636^35
 ;;^UTILITY(U,$J,358.3,9090,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9090,1,4,0)
 ;;=4^V10.63
 ;;^UTILITY(U,$J,358.3,9090,1,5,0)
 ;;=5^Hx Of Monocytic Leukemia
 ;;^UTILITY(U,$J,358.3,9090,2)
 ;;=Hx of Monocytic Leukemia^295234
 ;;^UTILITY(U,$J,358.3,9091,0)
 ;;=V11.2^^74^636^30
 ;;^UTILITY(U,$J,358.3,9091,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9091,1,4,0)
 ;;=4^V11.2
 ;;^UTILITY(U,$J,358.3,9091,1,5,0)
 ;;=5^Hx Of Dysthymia
 ;;^UTILITY(U,$J,358.3,9091,2)
 ;;=Hx of Dysthymia^295251
 ;;^UTILITY(U,$J,358.3,9092,0)
 ;;=V15.81^^74^636^46
 ;;^UTILITY(U,$J,358.3,9092,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9092,1,4,0)
 ;;=4^V15.81
 ;;^UTILITY(U,$J,358.3,9092,1,5,0)
 ;;=5^Noncompliance With Medical Treatment
 ;;^UTILITY(U,$J,358.3,9092,2)
 ;;=^295290
 ;;^UTILITY(U,$J,358.3,9093,0)
 ;;=V10.43^^74^636^37
 ;;^UTILITY(U,$J,358.3,9093,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9093,1,4,0)
 ;;=4^V10.43
 ;;^UTILITY(U,$J,358.3,9093,1,5,0)
 ;;=5^Hx Of Ovarian Ca
 ;;^UTILITY(U,$J,358.3,9093,2)
 ;;=Hx of Ovarian CA^295221
 ;;^UTILITY(U,$J,358.3,9094,0)
 ;;=V12.71^^74^636^38
 ;;^UTILITY(U,$J,358.3,9094,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9094,1,4,0)
 ;;=4^V12.71
 ;;^UTILITY(U,$J,358.3,9094,1,5,0)
 ;;=5^Hx Of Peptic Ulcer Disease
 ;;^UTILITY(U,$J,358.3,9094,2)
 ;;=^303400
 ;;^UTILITY(U,$J,358.3,9095,0)
 ;;=V10.46^^74^636^39
 ;;^UTILITY(U,$J,358.3,9095,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9095,1,4,0)
 ;;=4^V10.46
 ;;^UTILITY(U,$J,358.3,9095,1,5,0)
 ;;=5^Hx Of Prostate Cancer
 ;;^UTILITY(U,$J,358.3,9095,2)
 ;;=Hx of Prostate Cancer^295224
 ;;^UTILITY(U,$J,358.3,9096,0)
 ;;=V11.0^^74^636^40
 ;;^UTILITY(U,$J,358.3,9096,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9096,1,4,0)
 ;;=4^V11.0
 ;;^UTILITY(U,$J,358.3,9096,1,5,0)
 ;;=5^Hx Of Schizophrenia
 ;;^UTILITY(U,$J,358.3,9096,2)
 ;;=Hx of Schizophrenia^295249
 ;;^UTILITY(U,$J,358.3,9097,0)
 ;;=V10.83^^74^636^41
 ;;^UTILITY(U,$J,358.3,9097,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9097,1,4,0)
 ;;=4^V10.83
 ;;^UTILITY(U,$J,358.3,9097,1,5,0)
 ;;=5^Hx Of Skin Cancer (Non-Melanoma)
 ;;^UTILITY(U,$J,358.3,9097,2)
 ;;=^295241
 ;;^UTILITY(U,$J,358.3,9098,0)
 ;;=V15.1^^74^636^42
 ;;^UTILITY(U,$J,358.3,9098,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9098,1,4,0)
 ;;=4^V15.1
 ;;^UTILITY(U,$J,358.3,9098,1,5,0)
 ;;=5^Hx Of Surgery To Heart And Great Vessels
 ;;^UTILITY(U,$J,358.3,9098,2)
 ;;=^295283
 ;;^UTILITY(U,$J,358.3,9099,0)
 ;;=V15.82^^74^636^44
 ;;^UTILITY(U,$J,358.3,9099,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9099,1,4,0)
 ;;=4^V15.82
 ;;^UTILITY(U,$J,358.3,9099,1,5,0)
 ;;=5^Hx Of Tobacco Use (Not Current)
 ;;^UTILITY(U,$J,358.3,9099,2)
 ;;=Hx of Tobacco Use (not current)^303405
 ;;^UTILITY(U,$J,358.3,9100,0)
 ;;=V12.01^^74^636^43
 ;;^UTILITY(U,$J,358.3,9100,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9100,1,4,0)
 ;;=4^V12.01
 ;;^UTILITY(U,$J,358.3,9100,1,5,0)
 ;;=5^Hx Of TB
 ;;^UTILITY(U,$J,358.3,9100,2)
 ;;=Hx of TB^303393
 ;;^UTILITY(U,$J,358.3,9101,0)
 ;;=V13.01^^74^636^31
 ;;^UTILITY(U,$J,358.3,9101,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9101,1,4,0)
 ;;=4^V13.01
 ;;^UTILITY(U,$J,358.3,9101,1,5,0)
 ;;=5^Hx Of Kidney Stones
 ;;^UTILITY(U,$J,358.3,9101,2)
 ;;=Hx of Kidney Stones^303403
 ;;^UTILITY(U,$J,358.3,9102,0)
 ;;=V12.51^^74^636^45
 ;;^UTILITY(U,$J,358.3,9102,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9102,1,4,0)
 ;;=4^V12.51
 ;;^UTILITY(U,$J,358.3,9102,1,5,0)
 ;;=5^Hx Of Venous Thrombosis And Embolism
 ;;^UTILITY(U,$J,358.3,9102,2)
 ;;=^303397
 ;;^UTILITY(U,$J,358.3,9103,0)
 ;;=V17.89^^74^636^3
 ;;^UTILITY(U,$J,358.3,9103,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9103,1,4,0)
 ;;=4^V17.89
 ;;^UTILITY(U,$J,358.3,9103,1,5,0)
 ;;=5^Fam Hx Musculosk Dis
 ;;^UTILITY(U,$J,358.3,9103,2)
 ;;=^332861
 ;;^UTILITY(U,$J,358.3,9104,0)
 ;;=V12.54^^74^636^29
 ;;^UTILITY(U,$J,358.3,9104,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9104,1,4,0)
 ;;=4^V12.54
 ;;^UTILITY(U,$J,358.3,9104,1,5,0)
 ;;=5^HX of TIA
 ;;^UTILITY(U,$J,358.3,9104,2)
 ;;=^335309
 ;;^UTILITY(U,$J,358.3,9105,0)
 ;;=V12.54^^74^636^28
 ;;^UTILITY(U,$J,358.3,9105,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9105,1,4,0)
 ;;=4^V12.54
 ;;^UTILITY(U,$J,358.3,9105,1,5,0)
 ;;=5^HX of Stroke w/o Residuals
 ;;^UTILITY(U,$J,358.3,9105,2)
 ;;=^335309
 ;;^UTILITY(U,$J,358.3,9106,0)
 ;;=V15.88^^74^636^26
 ;;^UTILITY(U,$J,358.3,9106,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9106,1,4,0)
 ;;=4^V15.88
 ;;^UTILITY(U,$J,358.3,9106,1,5,0)
 ;;=5^HX of Falls
 ;;^UTILITY(U,$J,358.3,9106,2)
 ;;=^332859
 ;;^UTILITY(U,$J,358.3,9107,0)
 ;;=V13.59^^74^636^27
 ;;^UTILITY(U,$J,358.3,9107,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9107,1,4,0)
 ;;=4^V13.59
 ;;^UTILITY(U,$J,358.3,9107,1,5,0)
 ;;=5^HX of Musculoskletl Dis NEC
 ;;^UTILITY(U,$J,358.3,9107,2)
 ;;=^295268
 ;;^UTILITY(U,$J,358.3,9108,0)
 ;;=V12.04^^74^636^58
 ;;^UTILITY(U,$J,358.3,9108,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9108,1,4,0)
 ;;=4^V12.04
 ;;^UTILITY(U,$J,358.3,9108,1,5,0)
 ;;=5^Personal H/O MRSA infection
 ;;^UTILITY(U,$J,358.3,9108,2)
 ;;=^336780
 ;;^UTILITY(U,$J,358.3,9109,0)
 ;;=V62.22^^74^636^61
 ;;^UTILITY(U,$J,358.3,9109,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9109,1,4,0)
 ;;=4^V62.22
 ;;^UTILITY(U,$J,358.3,9109,1,5,0)
 ;;=5^Personal H/O Retrn Military Deploy
 ;;^UTILITY(U,$J,358.3,9109,2)
 ;;=^336807
 ;;^UTILITY(U,$J,358.3,9110,0)
 ;;=V13.51^^74^636^59
 ;;^UTILITY(U,$J,358.3,9110,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9110,1,4,0)
 ;;=4^V13.51
 ;;^UTILITY(U,$J,358.3,9110,1,5,0)
 ;;=5^Personal H/O Pathological FX
 ;;^UTILITY(U,$J,358.3,9110,2)
 ;;=^336781
 ;;^UTILITY(U,$J,358.3,9111,0)
 ;;=V15.51^^74^636^63
 ;;^UTILITY(U,$J,358.3,9111,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9111,1,4,0)
 ;;=4^V15.51
